• Publications
  • Influence
Enhanced spatial discrimination learning in rats following 5,7-DHT-induced serotonergic deafferentation of the hippocampus
Learning in rats trained in the Stone 14-unit T-maze, a complex, positively reinforced spatial discrimination task was assessed following cytotoxic (5,7-dihydroxytryptamine; 5,7-DHT) deafferentationExpand
Regulated lentiviral NGF gene transfer controls rescue of medial septal cholinergic neurons.
Nerve growth factor (NGF) has been shown to promote survival and function of cholinergic neurons in the basal forebrain in various models of neuronal degeneration in rodents and primates. We examinedExpand
Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons
Treatment of degenerating basal forebrain cholinergic neurons with nerve growth factor (NGF) in Alzheimer's disease has long been contemplated, but an effective and safe delivery method has beenExpand
536. Design and production of an AAV2 vector encoding a chimeric cDNA allowing efficient secretion of functional human neurturin from human cells
Neurturin (NTN) belongs to the glial cell line-derived neurotrophic factor (GDNF) family of ligands (GFL) and has been found to be a potent survival factor for midbrain dopaminergic neurons.Expand
227. Anatomical and Behavioral Effects of AAV2-Mediated Delivery of Neurturin to the Rat Striatum Prior to 6-Hydroxydopamine Induced Nigrostriatal Degeneration
The cardinal symptoms of Parkinson's disease (PD) are due to striatal dopamine insufficiency secondary to degeneration of dopaminergic neurons in the substantia nigra (SN) pars compacta. SeveralExpand
513. A Simple Method To Ensure Titer Conservation of AAV2 Vector Preparations Delivered with Stainless Steel Needles
Ceregene is developing AAV2-based gene therapy vectors encoding nerve growth factor (NGF) (CERE-110) and neurturin (NTN) (CERE-120) for the treatment of Alzheimer's and Parkinson's diseasesExpand